Julie Graff, MD, Oncology, Portland, OR, VA Portland Healthcare System

JulieNicoleGraffMD

Oncology Portland, OR

Hematologic Oncology

Physician

Dr. Graff is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Graff's full profile

Already have an account?

Education & Training

  • Oregon Health & Science University
    Oregon Health & Science UniversityFellowship, Hematology/Oncology, 2006 - 2009
  • Oregon Health & Science University
    Oregon Health & Science UniversityResidency, Internal Medicine, 2003 - 2006
  • George Washington University School of Medicine
    George Washington University School of MedicineClass of 2003

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2006 - 2021
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resis... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Addressing Therapeutic Challenges for Geriatric Patients with mCRPC
    Addressing Therapeutic Challenges for Geriatric Patients with mCRPCOctober 24, 2020 18:58
  • Expert Addresses Abiraterone Versus Docetaxel in Castration-Sensitive Prostate Cancer
    Expert Addresses Abiraterone Versus Docetaxel in Castration-Sensitive Prostate CancerOctober 24, 2020 18:57
  • Drake Highlights PARP Inhibitors, Immunotherapy in Prostate Cancer
    Drake Highlights PARP Inhibitors, Immunotherapy in Prostate CancerOctober 24, 2020 18:56
  • Join now to see all

Professional Memberships

Hospital Affiliations